Jerald Cox

Micro Therapeutics, Inc. develops, manufactures and markets invasive medical devices for the diagnosis and treatment of vascular diseases. Its products include infusion catheters, ballon catheters, delivery catheters, guide wires, infusion wires, and thrombolytic brushes. The company was founded in 1993 and is headquartered in Irvine, CA

ROX Medical, Inc. manufactures medical ultrasonic scanning devices. It offers ROX Coupler that is intended for use in patients with treatment resistant hypertension to lower blood pressure by reducing peripheral vascular resistance and improving vascular compliance; and in patients with chronic obstructive pulmonary disease to improve breathing, reduce symptoms of chronic bronchitis, and improve exercise tolerance. The company was founded by Rodney Brenneman and John Faul in 2004 and is headquartered in San Clemente, CA.

Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.

Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA.

Advanced Animal Diagnostics, Inc. develops integrated systems and solutions for the detection of animal diseases. The firm engages in the researching, developing and commercializing on-farm diagnostic tests, such as QScout MLD for early detection of subclinical mastitis in dairy cows. It also provides solutions for the diagnosis and treatment of veterinary health problems including mastitis and other animal diseases. The company was founded by Rodolfo Rodriguez and Victor M. Minton in July 2001 and is headquartered in Durham, NC.

Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA.

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.

Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY.

Sensitech, Inc. provides cold chain solutions for monitoring temperature-sensitive and perishable products. Its products encompasses in software, dataloggers, logistics security, chemical and electronic indicator, strip chart recorders, ethylene absorption, facility monitoring, and accessories. The company was founded by Ernest M. Santin in 1990 and is headquartered in Beverly, MA.

Prism Venture Management LLC (Prism Venture Management) is a venture capital firm founded in 1996 by Bob C. Fleming and John L. Brooks. The firm is headquartered in Needham, Massachusetts.

Mid-Atlantic Venture Funds (Mid-Atlantic Venture Funds) is a venture capital firm founded in 1984 by Fred J. Beste. The firm is headquartered in Bethlehem, Pennsylvania.

Visiogen, Inc. develops products for cataract and refractive patients. It offers synchrony dual-optic accommodating intraocular lens and pre-loaded injector, which provide distance, intermediate, and near vision to presbyopic cataract patients. The company was founded on March 19, 2001 and is headquartered in Abbott Park, IL.

Michigan Ross Zell Lurie Institute / Venture Capital/ (Zell Lurie Institute) is a venture capital subsidiary of Zell Lurie Institute for Entrepreneurial Studies Studies founded in 1997 by Samuel Zell, Ann Lurie and Robert H. Lurie. The firm is headquartered in Ann Arbor, Michigan.

Portaero, Inc. develops and manufactures medical devices. The company was founded on May 11, 2007 and is headquartered in Menlo Park, CA.

Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd

Adventus Ventures LLC (Adventus Ventures) is a venture capital firm founded in 2017 by Shawn Moaddeb and James Hill. The firm is headquartered in Irvine, California.

Gregor Diagnostics, Inc. develops and manufactures molecular diagnostics screening tests for prostate cancer. It provides proprietary system to maintain biomarker stability in the seminal fluid. The company was founded by Tobias Zutz in February 2016 and is headquartered in Madison, WI.

Spectrawave, Inc. provides medical devices. The company is headquartered in Waltham, MA.

Maxwell Biomedical, Inc. develops medical devices. The company was founded by Randy Werneth, Medhi Razavi and Aydin Babakhani and is headquartered in Solana Beach, CA.

E-Merge Capital Management LLC is a venture capital firm founded in 2021. The firm is headquartered in Solana Beach, California.

Arga Medtech SA develops pulsed field ablation and electroporation systems for treating cardiac arrhythmias. The company is based in Epalinges, Switzerland. The Swiss company was founded by David Neale, Randy Werneth. David Neale has been the CEO since incorporation.

Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC.